TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03248583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Default option
Description: The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
Study: NCT00345189

Intervention type: DRUG
Group type: OTHER
Intervention: CNF2024
Description: CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: CNF2024
Description: CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.
Study: NCT01733342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Celsite chemoport implantation
Description: Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: chemoport implantation will be done under local anesthesia using lidocaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia
Description: chemoport implantation will be done under local anesthesia using lidocaine.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humanport chemoport implantation
Description: Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
Study: NCT02873650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose of 100 mg dabrafenib on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose of 100 mg dabrafenib on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: Single dose of 100 mg dabrafenib on Day 1
Study: NCT02830672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical release A1 pulley for Trigger finger of the hand

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical release A1 pulley for Trigger finger of the hand
Study: NCT05713773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coated beads glucose (8 g) and caffeine anhydrous
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coated beads glucose (8 g) and caffeine anhydrous
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coated beads glucose (8 g) and caffeine anhydrous
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: coated beads glucose (8 g)
Description: After an overnight fasting of about 10 hours the subjects were administered glucose (8 g) starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: uncoated beads glucose (8 g) and caffeine anhydrous
Description: After an overnight fasting of about 10 hours the subjects were administered either glucose (8 g) or glucose (8 g) and caffeine starting at 8:00 (time 0; administration time was staggered beginning at 8:00 for the first group of subjects) in sitting position on Day 1.
Study: NCT00512746

Intervention type: OTHER
Group type: OTHER
Intervention: cytology and cytometry specimen collection procedure
Description: Samples tested and further interventions added if positive

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest x ray
Description: Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.

Intervention type: OTHER
Group type: OTHER
Intervention: Chest x ray
Description: Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autofluorescence bronchoscopy
Description: The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CT scan
Description: All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
Study: NCT01085552

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Beta
Description: Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
Study: NCT00521924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infliximab 3 mg/kg and basic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.
Description: Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
Study: NCT01454245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.
Study: NCT02713035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self help intervention
Description: For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
Study: NCT00141895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 tablets 200 micrograms Vaginal route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 tablets of 200 micrograms Sublingual route
Study: NCT03764163

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT Scans
Description: volume scans, perfusion scan, ventilation scan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: proton scans, hyperpolarized 3-Helium scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xenon gas
Description: ventilation CT scans
Study: NCT02615470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced immunization delivery model
Description: Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunization update
Description: Basic immunization update online webinar will summarize changes in immunization schedules.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunization update
Description: Basic immunization update online webinar will summarize changes in immunization schedules.
Study: NCT02668653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Study: NCT00392353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT03971994

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facial expression recognition task
Description: We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facial expression recognition task
Description: We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facial expression recognition task
Description: We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
Study: NCT02794454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeezOn Ultra-1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HeezOn Ultra-2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04047160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-724
Description: Twice a week for 4 hours continuous intravenous administration of OP-724
Study: NCT03627767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered as two tablets to be taken orally once daily for 40 weeks
Study: NCT04472143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Transdermal Delivery System
Description: A total of 60 patients with HER2-positive advanced breast cancer who are scheduled to receive pirotinib combined with capecitabine will be enrolled. A single transdermal patch will be applied to the subject' upper outer arm 24-48 hours before chemotherapy for 7 days. The observation period will be from the time of enrollment to 14 days (± 7 days) after the removal of granisetron patch.
Study: NCT01717287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir Film-coated Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir Chewable Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Anti-Retroviral Therapy
Description: At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Anti-Retroviral Therapy
Description: At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
Study: NCT03561792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm ultrasound
Description: In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
Study: NCT04414371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga Namaskar and Nadi Shuddhi

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: Yoga Namaskar and Nadi Shuddhi
Study: NCT03712436

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard oncological care
Description: Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
Study: NCT00947362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electro-thermo-coagulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro-thermo-coagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAC N-055
Description: moist wound treatment plus 0.05 % pharmaceutical chlorite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: physiological saline
Study: NCT02744300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BABI-2 Lifestyle Intervention
Description: Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
Study: NCT00453648

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White-fleshed sweet potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange-fleshed sweet potatoes (boiled)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange-fleshed sweet potatoes (fried)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WFSP and capsule of retinyl palmitate
Study: NCT00930722

Intervention type: DRUG
Intervention: quinapril
Description: per label as non interventional study
Study: NCT02963038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19-targeting CAR T cells
Description: Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
Study: NCT02801955

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: radical total/subtotal gastrectomy with D2 lymph node dissection

Intervention type: PROCEDURE
Intervention: sampling of peritoneal washing aspirate
Description: After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
Study: NCT00295633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone
Description: Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Tablets, Oral, 500-2500 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2500 mg, as needed (12 months LT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Tablets, Oral, 500-2500 mg, as needed (12 months LT)
Study: NCT00520455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms
Description: levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
Study: NCT01956149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
Study: NCT01043679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Utapine
Description: Efficacy and Safety of Utapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: Efficacy and Safety of Seroquel
Study: NCT02248259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Oral single dose of BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Oral single dose of BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Oral single dose of BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Oral single dose of BI 409306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
Study: NCT03486886

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA -PET/CT scanning
Description: PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and \[18F\]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following \[18F\]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis).